公开(公告)号：US20200165350A1

公开(公告)日：2020-05-28

申请号：US16618525

申请日：2018-05-31

申请人： Health Research, Inc.

发明人： Ben K. SEON

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61P35/04

摘要： Provided are methods that involve administering to an individual in need thereof an immune checkpoint inhibitor and a monoclonal antibody (mAb) or antigen binding fragment thereof, wherein the mAb or the fragment thereof binds with specificity to human endoglin. For cancer patients, the administration results in inhibition of tumor growth and/or inhibition of metastasis, and/or prolongation of the life of the individual.

公开(公告)号：US20240101701A1

公开(公告)日：2024-03-28

申请号：US18546394

申请日：2022-02-17

申请人： Health Research, Inc.

发明人： Leonid CHERKASSKY ,  Richard KOYA ,  Kunle ODUNSI ,  Ben K. SEON

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

CPC分类号： C07K16/2896 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C12N5/0636 ,  A61K2239/29 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.

公开(公告)号：US20200087389A1

公开(公告)日：2020-03-19

申请号：US16682029

申请日：2019-11-13

申请人： Tracon Pharmaceuticals, Inc. ,  Health Research, Inc.

发明人： Charles P. THEUER ,  Ben K. SEON

IPC分类号： C07K16/22 ,  C07K16/30 ,  C07K16/28

摘要： The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.